A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Members of the JAK family of nonreceptor tyrosine kinases play a critical role in the growth and progression of many cancers and in inflammatory diseases. JAK2 has emerged as a leading therapeutic target for oncology, providing a rationale for the development of a selective JAK2 inhibitor. A program to optimize selective JAK2 inhibitors to combat cancer while reducing the risk of immune suppression associated with JAK3 inhibition was undertaken. The structure-activity relationships and biological evaluation of a novel series of compounds based on a 1,2,4-triazolo[1,5-a]pyridine scaffold are reported. Para substitution on the aryl at the C8 position of the core was optimum for JAK2 potency (17). Substitution at the C2 nitrogen position was required for cell potency (21). Interestingly, meta substitution of C2-NH-aryl moiety provided exceptional selectivity for JAK2 over JAK3 (23). These efforts led to the discovery of CEP-33779 (29), a novel, selective, and orally bioavailable inhibitor of JAK2.

[1]  K. T. Potts,et al.  1,2,4-Triazoles. XXV. The effect of pyridine substitution on the isomerization of s-Triazolo[4,3-a] pyridines into s-Triazolo[1,5-a] pyridines† , 1970 .

[2]  Jennifer L. Mason,et al.  2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation. , 2011, Bioorganic & Medicinal Chemistry Letters.

[3]  H. Kantarjian,et al.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond , 2011, Nature Reviews Drug Discovery.

[4]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[5]  T. Clackson,et al.  Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[6]  B. Ogorevc,et al.  Cyanoamino compounds in synthesis syntheses of some heterocycles , 1983 .

[7]  P. Dobrzanski,et al.  Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer , 2012, Molecular Cancer Therapeutics.

[8]  K. T. Potts,et al.  1,2,4-Triazoles. XIII. Derivatives of the s-Triazolo[1,5-a]pyridine Ring System1a , 1966 .

[9]  M. Nevalainen,et al.  Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. , 2007, Endocrinology.

[10]  B. Druker,et al.  CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.

[11]  M. Nevalainen,et al.  Signal transducer and activator of transcription 5 A / B in prostate and breast cancers , 2008 .

[12]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[13]  Anders Poulsen,et al.  Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho , 2011, Journal of medicinal chemistry.

[14]  T. Morio,et al.  Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. , 2006, Immunity.

[15]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[16]  Jennifer L. Mason,et al.  Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases. , 2012, Bioorganic & medicinal chemistry letters.

[17]  V. Imbert,et al.  Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. , 2006, Cellular signalling.

[18]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[19]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[20]  D. Gabrilovich,et al.  Targeting of Jak/STAT pathway in antigen presenting cells in cancer. , 2007, Current cancer drug targets.

[21]  S. Shepard,et al.  Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans , 2010, Drug Metabolism and Disposition.

[22]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[23]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[24]  Pawel Dobrzanski,et al.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. , 2008, Blood.

[25]  S. Roy,et al.  1,2,4-Triazoles. XIV. Reactions of the s-Triazolo[4,3-a]pyridine Ring System1a,b , 1966 .

[26]  Marja T Nevalainen,et al.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers. , 2008, Endocrine-related cancer.

[27]  Jennifer L. Mason,et al.  Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition. , 2011, Assay and drug development technologies.

[28]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.

[29]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[30]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[31]  Catriona Jamieson,et al.  Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Xie,et al.  Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological Grade , 2004, Cancer Research.

[33]  P. Dobrzanski,et al.  A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis , 2011, Arthritis research & therapy.